Capital International Inc. CA Sells 110,328 Shares of Corteva, Inc. $CTVA

Key Points

• Capital International Inc. CA sold 110,328 shares of Corteva, trimming its position by 14.5 to 648,699 shares (about 0.10% of the company) valued at roughly $43.87 million.
• Corteva reported Q results with EPS of $0.22 (in line with estimates) but revenue of $3.91 billion missed the $4.23 billion consensus and was down 1.7% YoY; the company set FY2026 guidance of 3.45–3.70 EPS and analysts have a consensus "Moderate Buy" target of $82.90.
• Corteva declared a quarterly dividend of $0.18 per share (annualized $0.72, yield 0.9%) with an ex-dividend date of March 2 and payment on March 16.

Capital International Inc. CA lowered its position in Corteva, Inc. (NYSE:CTVA - Free Report) by 14.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 648,699 shares of the company's stock after selling 110,328 shares during the period. Capital International Inc. CA owned 0.10% of Corteva worth $43,872,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. Total Investment Management Inc. bought a new stake in Corteva during the second quarter valued at $27,000. Activest Wealth Management grew its stake in Corteva by 118.3% during the third quarter. Activest Wealth Management now owns 369 shares of the company's stock worth $25,000 after purchasing an additional 200 shares during the period. True Wealth Design LLC increased its holdings in Corteva by 209.5% in the third quarter. True Wealth Design LLC now owns 390 shares of the company's stock worth $26,000 after purchasing an additional 264 shares in the last quarter. Twin Peaks Wealth Advisors LLC bought a new position in shares of Corteva during the 2nd quarter worth approximately $29,000. Finally, Redmont Wealth Advisors LLC bought a new stake in shares of Corteva in the 3rd quarter valued at $29,000. Institutional investors own 81.54% of the company's stock.

Corteva Price Performance

Shares of NYSE CTVA opened at $78.36 on Tuesday. The company has a market capitalization of $52.70 billion, a PE ratio of 49.59, a PEG ratio of 2.63 and a beta of 0.72. The company has a quick ratio of 0.96, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The stock's 50 day moving average price is $73.22 and its 200-day moving average price is $69.04. Corteva, Inc. has a twelve month low of $53.40 and a twelve month high of $80.90.

Corteva (NYSE:CTVA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 EPS for the quarter, meeting analysts' consensus estimates of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The company had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same period last year, the business posted $0.32 earnings per share. Corteva's revenue was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, equities analysts anticipate that Corteva, Inc. will post 2.96 EPS for the current year.

Corteva Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 16th. Stockholders of record on Monday, March 2nd will be paid a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Monday, March 2nd. Corteva's payout ratio is presently 45.57%.

Insider Buying and Selling at Corteva

In related news, insider Brian Titus sold 8,311 shares of the business's stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $76.55, for a total value of $636,207.05. Following the transaction, the insider directly owned 8,090 shares of the company's stock, valued at approximately $619,289.50. The trade was a 50.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.15% of the company's stock.

Wall Street Analysts Forecast Growth

CTVA has been the subject of several research analyst reports. Royal Bank Of Canada lifted their price target on shares of Corteva from $80.00 to $89.00 and gave the company an "outperform" rating in a research note on Thursday, February 5th. Weiss Ratings restated a "hold (c-)" rating on shares of Corteva in a report on Monday, December 29th. BNP Paribas Exane boosted their price target on shares of Corteva from $72.00 to $74.00 in a research note on Monday. Mizuho boosted their target price on shares of Corteva from $80.00 to $82.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 17th. Finally, Wall Street Zen downgraded Corteva from a "buy" rating to a "hold" rating in a research note on Saturday, February 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $82.90.

Corteva Profile

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.